Thyroglobulin measurement in differentiated thyroid carcinoma management.

Area of Science:

• Oncology
• Endocrinology
• Nuclear Medicine

Background:

• Differentiated thyroid cancer (DTC) has a good prognosis, with total thyroidectomy and iodine-131 (¹³¹I) remnant ablation as standard initial treatment.
• Current follow-up relies on serum thyroglobulin (Tg) and neck ultrasound.
• Tg presence post-treatment indicates persistent or recurrent DTC.

Purpose of the Study:

• To review optimized strategies for serum Tg measurement in DTC follow-up.
• To highlight the role of sensitive Tg assays in detecting recurrence.
• To discuss the integration of Tg testing with imaging for efficient DTC surveillance.

Main Methods:

• Review of clinical and technical improvements in Tg assay sensitivity.
• Discussion of TSH-stimulated Tg measurements versus assays without stimulation.
• Analysis of imaging modalities (¹³¹I scans, PET/CT) guided by Tg levels.

Main Results:

• Optimized Tg measurements, especially with highly sensitive assays, improve early detection of DTC recurrence.
• TSH-stimulated Tg testing can reveal occult disease.
• Increasing Tg levels in sensitive assays are reliable indicators of recurrence.

Conclusions:

• Enhanced Tg testing, particularly with sensitive assays, is crucial for early DTC recurrence detection.
• Rational use of imaging should be guided by Tg testing results.
• A limited follow-up protocol based on Tg testing can effectively detect DTC recurrence while reducing patient burden and costs.